Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Pediatric Radiology
Erschienen in: Pediatric Radiology 5/2021

01.05.2021 | Minisymposium: Pediatric MRI quality and safety

Safety issues related to intravenous contrast agent use in magnetic resonance imaging

verfasst von: Skorn Ponrartana, Michael M. Moore, Sherwin S. Chan, Teresa Victoria, Jonathan R. Dillman, Govind B. Chavhan

Erschienen in: Pediatric Radiology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Gadolinium-based contrast agents (GBCAs) have been used to improve image quality of MRI examinations for decades and have an excellent overall safety record. However, there are well-documented risks associated with GBCAs and our understanding and management of these risks continue to evolve. The purpose of this review is to discuss the safety of GBCAs used in MRI in adult and pediatric populations. We focus particular attention on acute adverse reactions, nephrogenic systemic fibrosis and gadolinium deposition. We also discuss the non-GBCA MRI contrast agent ferumoxytol, which is increasing in use and has its own risk profile. Finally, we identify special populations at higher risk of harm from GBCA administration.
Literatur
1.
Lohrke J, Frenzel T, Endrikat J et al (2016) 25 years of contrast-enhanced MRI: developments, current challenges and future perspectives. Adv Ther 33:1–28PubMedPubMedCentralCrossRef
2.
Runge VM, Stewart RG, Clanton JA et al (1983) Work in progress: potential oral and intravenous paramagnetic NMR contrast agents. Radiology 147:789–791PubMedCrossRef
3.
Mathur M, Jones JR, Weinreb JC (2020) Gadolinium deposition and nephrogenic systemic fibrosis: a radiologist's primer. Radiographics 40:153–162PubMedCrossRef
4.
Balzer T (2017) Presence of gadolinium (Gd) in the brain and body. Presentation to the medical imaging drugs advisory committee. United States Food and Drug Administration, Silver Spring
5.
Bleicher AG, Kanal E (2008) Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 191:W307–W311PubMedCrossRef
6.
Ramalho J, Semelka RC, Ramalho M et al (2016) Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol 37:1192–1198PubMedPubMedCentralCrossRef
7.
Grobner T (2006) Gadolinium — a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108PubMedCrossRef
8.
Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362PubMedCrossRef
9.
Kanda T, Ishii K, Kawaguchi H et al (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834–841PubMedCrossRef
10.
Errante Y, Cirimele V, Mallio CA et al (2014) Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Investig Radiol 49:685–690CrossRef
11.
McDonald RJ, McDonald JS, Kallmes DF et al (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275:772–782PubMedCrossRef
12.
Holowka S, Shroff M, Chavhan GB (2019) Use and safety of gadolinium based contrast agents in pediatric MR imaging. Indian J Pediatr 86:961–966PubMedCrossRef
13.
Mitsumori LM, Bhargava P, Essig M, Maki JH (2014) Magnetic resonance imaging using gadolinium-based contrast agents. Top Magn Reson Imaging 23:51–69PubMedCrossRef
14.
Kanda T, Oba H, Toyoda K et al (2016) Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol 34:3–9PubMedCrossRef
15.
16.
Frenzel T, Lengsfeld P, Schirmer H et al (2008) Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Investig Radiol 43:817–828CrossRef
17.
Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ (2017) Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging 46:338–353PubMedCrossRef
18.
Juluru K, Vogel-Claussen J, Macura KJ et al (2009) MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Radiographics 29:9–22PubMedCrossRef
19.
20.
21.
22.
23.
Wang YX, Hussain SM, Krestin GP (2001) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11:2319–2331PubMedCrossRef
24.
Pai AB, Garba AO (2012) Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med 3:77–85PubMedPubMedCentral
25.
Li W, Tutton S, Vu AT et al (2005) First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 21:46–52PubMedCrossRef
26.
Prince MR, Zhang HL, Chabra SG et al (2003) A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J Xray Sci Technol 11:231–240PubMed
27.
Ruangwattanapaisarn N, Hsiao A, Vasanawala SS (2015) Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. Pediatr Radiol 45:831–839PubMedCrossRef
28.
Luhar A, Khan S, Finn JP et al (2016) Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Pediatr Radiol 46:1332–1340PubMedCrossRef
29.
Toth GB, Varallyay CG, Horvath A et al (2017) Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int 92:47–66PubMedPubMedCentralCrossRef
30.
31.
Muehe AM, Siedek F, Theruvath AJ et al (2020) Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI. Theranostics 10:3612–3621PubMedPubMedCentralCrossRef
32.
Storey P, Lim RP, Chandarana H et al (2012) MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Investig Radiol 47:717–724CrossRef
33.
Dillman JR, Trout AT, Davenport MS (2018) Allergic-like contrast media reaction management in children. Pediatr Radiol 48:1688–1694PubMedCrossRef
34.
Behzadi AH, Zhao Y, Farooq Z, Prince MR (2018) Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology 286:731PubMedCrossRef
35.
McDonald JS, Hunt CH, Kolbe AB et al (2019) Acute adverse events following gadolinium-based contrast agent administration: a single-center retrospective study of 281,945 injections. Radiology 292:620–627PubMedCrossRef
36.
Dillman JR, Ellis JH, Cohan RH et al (2007) Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol 189:1533–1538PubMedCrossRef
37.
Forbes-Amrhein MM, Dillman JR, Trout AT et al (2018) Frequency and severity of acute allergic-like reactions to intravenously administered gadolinium-based contrast media in children. Investig Radiol 53:313–318CrossRef
38.
Walker DT, Davenport MS, McGrath TA et al (2020) Breakthrough hypersensitivity reactions to gadolinium-based contrast agents and strategies to decrease subsequent reaction rates: a systematic review and meta-analysis. Radiology 296:312–321PubMedCrossRef
39.
Blumfield E, Moore MM, Drake MK et al (2017) Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a quality and safety committee report. Pediatr Radiol 47:665–673PubMedCrossRef
40.
Schiller B, Bhat P, Sharma A (2014) Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther 36:70–83PubMedCrossRef
41.
Varallyay CG, Nesbit E, Horvath A et al (2018) Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: comparison to standard of care. J Magn Reson Imaging 48:441–448PubMedPubMedCentralCrossRef
42.
43.
Muehe AM, Feng D, von Eyben R et al (2016) Safety report of ferumoxytol for magnetic resonance imaging in children and young adults. Investig Radiol 51:221–227CrossRef
44.
Cowper SE, Bucala R, Leboit PE (2006) Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis — setting the record straight. Semin Arthritis Rheum 35:208–210PubMedCrossRef
45.
Swaminathan S, Horn TD, Pellowski D et al (2007) Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 357:720–722PubMedCrossRef
46.
Wagner B, Tan C, Barnes JL et al (2012) Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model. Am J Pathol 181:1941–1952PubMedCrossRef
47.
Attari H, Cao Y, Elmholdt TR et al (2019) A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis. Radiology 292:376–386PubMedCrossRef
48.
Jimenez SA, Artlett CM, Sandorfi N et al (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50:2660–2666PubMedCrossRef
49.
Daram SR, Cortese CM, Bastani B (2005) Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 46:754–759PubMedCrossRef
50.
Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157PubMedCrossRef
51.
Wertman R, Altun E, Martin DR et al (2008) Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248:799–806PubMedCrossRef
52.
Abu-Alfa AK (2011) Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis 18:188–198PubMedCrossRef
53.
Prince MR, Zhang H, Morris M et al (2008) Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248:807–816PubMedCrossRef
54.
Collidge TA, Thomson PC, Mark PB et al (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245:168–175PubMedCrossRef
55.
Nardone B, Saddleton E, Laumann AE et al (2014) Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatr Radiol 44:173–180PubMedCrossRef
56.
Abu Alfa AK (2010) Approach to the use of GBCA in patients with kidney disease. Presented at the fourth annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents, May 14-15, 2010, New York
57.
Elmholdt TR, Pedersen M, Jorgensen B et al (2011) Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark. Br J Dermatol 165:828–836PubMedCrossRef
58.
Swaminathan S, Shah SV (2007) New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 18:2636–2643PubMedCrossRef
59.
60.
61.
62.
Kirchin MA, Lorusso V, Pirovano G (2015) Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? Br J Radiol 88:20140526PubMedPubMedCentralCrossRef
63.
Prince MR, Zhang HL, Roditi GH et al (2009) Risk factors for NSF: a literature review. J Magn Reson Imaging 30:1298–1308PubMedCrossRef
64.
Othersen JB, Maize JC, Woolson RF, Budisavljevic MN (2007) Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 22:3179–3185PubMedCrossRef
65.
McWilliams RG, Frabizzio JV, De Backer AI et al (2020) Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study. J Magn Reson Imaging 51:607–614PubMedCrossRef
66.
Deray G, Rouviere O, Bacigalupo L et al (2013) Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol 23:1250–1259PubMedCrossRef
67.
Janus N, Launay-Vacher V, Karie S et al (2010) Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol 73:357–359PubMedCrossRef
68.
Amet S, Launay-Vacher V, Clement O et al (2014) Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the prospective Fibrose Nephrogenique Systemique study. Investig Radiol 49:109–115CrossRef
69.
Franano FN, Edwards WB, Welch MJ et al (1995) Biodistribution and metabolism of targeted and nontargeted protein-chelate-gadolinium complexes: evidence for gadolinium dissociation in vitro and in vivo. Magn Reson Imaging 13:201–214PubMedCrossRef
70.
Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Investig Radiol 39:138–142CrossRef
71.
Sieber MA, Lengsfeld P, Frenzel T et al (2008) Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 18:2164–2173PubMedCrossRef
72.
Maximova N, Gregori M, Zennaro F et al (2016) Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology 281:418–426PubMedCrossRef
73.
White GW, Gibby WA, Tweedle MF (2006) Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Investig Radiol 41:272–278CrossRef
74.
Xia D, Davis RL, Crawford JA, Abraham JL (2010) Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Acta Radiol 51:1126–1136PubMedCrossRef
75.
McDonald RJ, McDonald JS, Kallmes DF et al (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 285:546–554PubMedCrossRef
76.
Kanda T, Fukusato T, Matsuda M et al (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276:228–232PubMedCrossRef
77.
McDonald RJ, Levine D, Weinreb J et al (2018) Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. Radiology 289:517–534PubMedCrossRef
78.
McDonald JS, McDonald RJ, Jentoft ME et al (2017) Intracranial gadolinium deposition following gadodiamide-enhanced magnetic resonance imaging in pediatric patients: a case-control study. JAMA Pediatr 171:705–707PubMedPubMedCentralCrossRef
79.
Stanescu AL, Shaw DW, Murata N et al (2020) Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation. Pediatr Radiol 50:388–396PubMedCrossRef
80.
Zhang Y, Cao Y, Shih GL et al (2017) Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology 282:516–525PubMedCrossRef
81.
Radbruch A, Weberling LD, Kieslich PJ et al (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275:783–791PubMedCrossRef
82.
Radbruch A, Haase R, Kieslich PJ et al (2017) No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents. Radiology 282:699–707PubMedCrossRef
83.
Lee JY, Park JE, Kim HS et al (2017) Up to 52 administrations of macrocyclic ionic MR contrast agent are not associated with intracranial gadolinium deposition: multifactorial analysis in 385 patients. PLoS One 12:e0183916PubMedPubMedCentralCrossRef
84.
Tibussek D, Rademacher C, Caspers J et al (2017) Gadolinium brain deposition after macrocyclic gadolinium administration: a pediatric case-control study. Radiology 285:223–230PubMedCrossRef
85.
Ryu YJ, Choi YH, Cheon JE et al (2018) Pediatric brain: gadolinium deposition in dentate nucleus and globus pallidus on unenhanced T1-weighted images is dependent on the type of contrast agent. Investig Radiol 53:246–255CrossRef
86.
Renz DM, Kumpel S, Bottcher J et al (2018) Comparison of unenhanced T1-weighted signal intensities within the dentate nucleus and the globus pallidus after serial applications of gadopentetate dimeglumine versus gadobutrol in a pediatric population. Investig Radiol 53:119–127CrossRef
87.
Murata N, Gonzalez-Cuyar LF, Murata K et al (2016) Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Investig Radiol 51:447–453CrossRef
88.
Robert P, Lehericy S, Grand S et al (2015) T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Investig Radiol 50:473–480CrossRef
89.
Nunn AD, Wedeking P, Marinelli E et al (1996) Toxicity of gadolinium chelates in rodents. Acad Radiol 3:S333–S335
90.
Pietsch H, Raschke M, Ellinger-Ziegelbauer H et al (2011) The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Investig Radiol 46:48–56CrossRef
91.
Ray DE, Holton JL, Nolan CC et al (1998) Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats. AJNR Am J Neuroradiol 19:1455–1462PubMedPubMedCentral
92.
Roman-Goldstein SM, Barnett PA, McCormick CI et al (1991) Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: toxicity and MR imaging findings. AJNR Am J Neuroradiol 12:885–890PubMedPubMedCentral
93.
Burke LM, Ramalho M, AlObaidy M et al (2016) Self-reported gadolinium toxicity: a survey of patients with chronic symptoms. Magn Reson Imaging 34:1078–1080PubMedCrossRef
94.
Gulani V, Calamante F, Shellock FG et al (2017) Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 16:564–570PubMedCrossRef
95.
96.
97.
98.
Tirada N, Dreizin D, Khati NJ et al (2015) Imaging pregnant and lactating patients. Radiographics 35:1751–1765PubMedCrossRef
99.
Salomon LJ, Siauve N, Balvay D et al (2005) Placental perfusion MR imaging with contrast agents in a mouse model. Radiology 235:73–80PubMedCrossRef
100.
Palacios Jaraquemada JM, Bruno C (2000) Gadolinium-enhanced MR imaging in the differential diagnosis of placenta accreta and placenta percreta. Radiology 216:610–611PubMedCrossRef
101.
Novak Z, Thurmond AS, Ross PL et al (1993) Gadolinium-DTPA transplacental transfer and distribution in fetal tissue in rabbits. Investig Radiol 28:828–830CrossRef
102.
Puac P, Rodriguez A, Vallejo C et al (2017) Safety of contrast material use during pregnancy and lactation. Magn Reson Imaging Clin N Am 25:787–797PubMedCrossRef
103.
Webb JA, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (2005) The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 15:1234–1240PubMedCrossRef
104.
Tremblay E, Therasse E, Thomassin-Naggara I, Trop I (2012) Quality initiatives: guidelines for use of medical imaging during pregnancy and lactation. Radiographics 32:897–911PubMedCrossRef
105.
Ray JG, Vermeulen MJ, Bharatha A et al (2016) Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA 316:952–961PubMedCrossRef
106.
Mathur S, Pillenahalli Maheshwarappa R, Fouladirad S et al (2020) Emergency imaging in pregnancy and lactation. Can Assoc Radiol J 71:396–402PubMedCrossRef
107.
108.
Metadaten
Titel
Safety issues related to intravenous contrast agent use in magnetic resonance imaging
verfasst von
Skorn Ponrartana
Michael M. Moore
Sherwin S. Chan
Teresa Victoria
Jonathan R. Dillman
Govind B. Chavhan
Publikationsdatum
01.05.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Radiology / Ausgabe 5/2021
Print ISSN: 0301-0449
Elektronische ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-020-04896-7

Weitere Artikel der Ausgabe 5/2021

Pediatric Radiology 5/2021 Zur Ausgabe

Original Article

Clinical concordance with Image Gently guidelines for pediatric computed tomography: a study across 663,417 CT scans at 53 clinical facilities

Commentary

A call to action: education of radiology residents in child abuse imaging

Technical Innovation

Real-time magnetic resonance imaging in pediatric radiology — new approach to movement and moving children

Original Article

Rate of resident recognition of nonaccidental trauma: how well do residents perform?

Minisymposium: Pediatric MRI quality and safety

Establishing a magnetic resonance safety program

Original Article

Extracardiac imaging findings in COVID-19-associated multisystem inflammatory syndrome in children

Neu im Fachgebiet Radiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise